A double-blind, randomised, placebo controlled, single dose, two-period crossover study to investigate the therapeutic potential of the TRPV1 antagonist SB-705498 in treatment of subjects with rectal hypersensitivity including irritable bowel syndrome.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2018
At a glance
- Drugs GSK 705498 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 08 Nov 2007 Patient numbers amended from 42 to 1.
- 08 Nov 2007 Status changed from recruiting to discontinued.
- 24 May 2007 New trial record.